4Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease [ J ]. Am Heart J, 2005, 150:1115-1121.
5Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophrenia:a randomized double-blind controlled, short-term prospective study [ J ]. Schizophr Res, 2008,101 : 266- 272.
6Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antip-sychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial[ J ]. Lancet,2008,371 : 1085-1097.
7Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with halopefidol, olanzapine, or risperidone [ J ]. J Clin Psychiatry, 2007,68 : 1735- 1740.
8Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year:findings of a randomized clinical trial in a drug-naive population [ J ]. Schizophr Res ,2008 ,99 :13-22.
9Graham KA, Cho H, Brownley KA, et al. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects [ J ]. Schizophr Res, 2008, 101 : 287- 294.
10Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome [ J ] ? Sehizophr Res ,2007,89:91-100.
